DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20174797

Evaluation of cognition enhancing activity of pioglitazone in albino mice

Shruthi S. L., Kalabharathi H. L., Siddamma Amoghimath

Abstract


Background: Worldwide, 47.5 million people have dementia, with just over half (58%) living in low- and middle-income countries. Every year, there are 7.7 million new cases. The estimated proportion of the general population aged 60 and over with dementia at a given time is between 5 to 8 per 100 people. The total number of people with dementia is projected to be 75.6 million in 2030 and almost triple by 2050 to 135.5 million.

Methods: All animals were allowed to acclimatize with laboratory conditions at least two weeks before starting the experiment and they were maintained under the same condition throughout the experiment. They were given food and water ad libitum. The experiments were performed as per the Committee for the Purpose of Control and Supervision on Experiments on Animals (CPCSEA) guidelines. The animals were subjected to experimentation between 0900-1600 hours in noise free atmosphere with ambient temperature 23-300ºC.

Results: The Pioglitazone treated groups showed statistically significant results in the SDL when compared to the control group (p<0.01 on both days) and the scopolamine group (p<0.01 on both days) on both acquisition day and retention day.

Conclusions: There was no significant difference in SDL in standard and Pioglitazone treated groups on both acquisition day and retention day.


Keywords


Albino mice, Cognition, Pioglitazone

Full Text:

PDF

References


Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780-6.

Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature. 2006;443(7113):796-802.

Horton R. GBD 2010: understanding disease, injury and risk. The Lancet. 2012;380(9859):2053-4.

Dementia. Fact sheet N° 362. March 2015 [accessed 24 September 2015]. Available at: http://www.who.int/mediacentre/factsheets/fs362/en/

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A. Global prevalence of dementia: a Delphi consensus study. The lancet. 2006 Jan 6;366(9503):2112-7.

Forette F, Boller F. Hypertension and the risk of dementia in the elderly. The American J of Med. 1991;90(3).

World Health Organization. Population Ageing: A Public Health Challenge. Fact Sheet No. 135. Geneva: World Health Organization; 1998.

Mathuranath PS, George A, Ranjith N, Justus S, Kumar MS, Menon R, et al. Incidence of Alzheimer’s disease in India: A 10 years follow-up study. Neurology India. 2012 Nov;60(6):625.

Gaugler j, Bryan J, Tricia J. Alzheimer’s Association. 2013 Alzheimer’s disease Facts and Figures. Alzheimer’s & Dementia. 2013;8(2):14-23.

Murali DP. Non-Cholinergic Strategies for Treating and Preventing Alzheimer’s Disease. CNS Drugs. 2002;16(12):811-24.

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702-16.

McGaugh JL. Amygdala: role in modulation of memory storage. In the Amygdala: A Functional Analysis; 2nd Ed. (Aggleton, J.P., ed.), Oxford University Press; 2000:391-423.

Mori E, Ikeda M, Hirono N, Kitagaki H, Imamura T. Amygdalar volume and emotional memory in Alzheimer's disease. Am J Psychiatry. 1999;156(2):216-22.

Reddy DS. Assessment of nootropic and amnestic activity of centrally acting agents. Indian J Pharmacol. 1997;29:208-21.

Nakajima M, Inui A, Miura M, Hirosue Y, Okita M. Negative and positive effects of intracerebroventricular scopolamine on memory in mice undergoing passive avoidance and escape tests. Brain Res Bull. 1994;34(4):375-80.

Kaur B, Singh N, Jaggi AS. Exploring mechanism of pioglitazone‐induced memory restorative effect in experimental dementia. Fundamental & clinical pharmacology. 2009 Oct 1;23(5):557-66.

Achliya G, Barabde U, Wadodkar S, Dorle A. Studies on the effects of Bramhi ghirta, an polyherbal formulation on learning and memory paradigms in experimental animals. Ind J Pharmacol. 2004;36(3):159-62.

Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur J Pharmacol. 1991;194(1):71-6.

Bezprozvanny I, Hiesinger PR. The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol Neurodegener. 2013;8:23.